source
- BrainChild secures $116M to advance CAR-T therapies for rare pediatric brain tumorsBrainChild Bio, a Seattle‑based biotech spun out of Seattle Children’s Hospital, announced it has raised $116 million in venture financing. The capital will fund the development of its CAR‑T cell t…
- Novartis and Ionis's pelacarsen fails to cut heart events despite lowering Lp(a) levelsNovartis and Ionis reported that pelacarsen, an RNA therapy aimed at lowering lipoprotein(a), did not reduce major cardiovascular events in a Phase 3 trial of over 8,000 patients. The study compare…